Answers are grounded in this paper and cite their sources.
Perspective evaluates opportunities and limitations for mRNA tuberculosis vaccines, highlighting strategies to optimize delivery and lung-localized immunity.
Tuberculosis (TB) vaccine development remains challenging due to the complex biology of M. tuberculosis infection and the absence of established correlates of protection. mRNA platforms can induce strong systemic humoral and effector immunity and offer several potential advantages; however, limited lung-localised immunity may restrict current formulations. This Perspective examines these challenges and discusses strategies to optimise mRNA vaccine design, formulation and delivery to improve protective immunity against TB.
No takes yet. Share an insight, caveat, or question.
Chan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: